# US 2023/0065562 A1 · Dual controls for therapeutic cell activation or elimination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065562 A1
- Document ID: US20230065562A1
- Status: Published application
- Kind: A1
- Application number: 17/219,116
- Filed: 2021-03-31
- Published: 2023-03-02
- Earliest claimed: 2015-12-14
- Assignees: Bellicum Pharmaceuticals, Inc.
- Applicants: Bellicum Pharmaceuticals, Inc.
- Inventors: Joseph Henri Bayle; MyLinh Thi Duong; Matthew Robert Collinson-Pautz; Aaron Edward Foster; David Micheal Spencer
- Web page: https://patentgrep.com/patent/US20230065562A1

## CPC

- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4217: {Receptors for interleukins [IL]}
- A61K 40/427: {PRAME}
- A61K 40/4274: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/90: Isomerases (5.)
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 304/22062: Caspase-9 (3.4.22.62)
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/515: {Animal cells}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2239/23: On/off switch
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/54: Pancreas
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using molecular switches that employ distinct heterodimerizer ligands, in conjunction with other multimeric ligands. The technology may be used, for example to activate or eliminate cells used to promote engraftment, to treat diseases or condition, or to control or modulate the activity of therapeutic cells that express chimeric antigen receptors or recombinant T cell receptors.

## Claims

### Claim 1

A modified cell, comprising
a) a first polynucleotide encoding a chimeric pro-apoptotic polypeptide, wherein the chimeric pro-apoptotic polypeptide comprises
(i) a pro-apoptotic polypeptide region;
(ii) a FKBP12-Rapamycin-Binding (FRB) domain polypeptide, or FRB variant polypeptide region; and
(iii) a FKBP12 or FKBP12 variant polypeptide region (FKBP12v); and
b) a second polynucleotide encoding a chimeric costimulating polypeptide, wherein the chimeric costimulating polypeptide comprises two FKBP12 variant polypeptide regions and
i) a MyD88 polypeptide region or a truncated MyD88 polypeptide region lacking the TIR domain; or
ii) a MyD88 polypeptide region or a truncated MyD88 polypeptide region lacking the TIR domain, and a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain.

### Claim 2 (depends on 1)

The modified cell of claim 1, wherein the chimeric costimulating polypeptide comprises two FKBP12 variant polypeptide regions, a truncated MyD88 polypeptide region lacking the TIR domain, and a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain.

### Claim 3 (depends on 1)

The modified cell of claim 1, wherein the cell further comprises a third polynucleotide encoding a chimeric antigen receptor or a recombinant T cell receptor.

### Claim at position 4

-7. (canceled)

### Claim 8 (depends on 1)

The modified cell of claim 1, wherein the cell is a T cell, tumor infiltrating lymphocyte, NK-T cell, or NK cell.

### Claim at position 6

-15. (canceled)

### Claim 16

A modified cell comprising
a) a first polynucleotide encoding a chimeric pro-apoptotic polypeptide, wherein the chimeric pro-apoptotic polypeptide comprises
i) a pro-apoptotic polypeptide region; and
ii) a FKBP12 variant polypeptide region; and
b) a second polynucleotide encoding a chimeric costimulating polypeptide, wherein the chimeric costimulating polypeptide comprises
i) a FKBP12-Rapamycin Binding (FRB) domain polypeptide or FRB variant polypeptide region;
ii) a FKBP12 polypeptide or FKBP12 variant polypeptide region; and
iii) a MyD88 polypeptide region or a truncated MyD88 polypeptide region lacking the TIR domain, or a MyD88 polypeptide region, or a truncated MyD88 polypeptide region lacking the TIR domain and a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain.

### Claim 17 (depends on 16)

The modified cell of claim 16, wherein the chimeric costimulating polypeptide comprises a truncated MyD88 polypeptide region lacking the TIR domain and a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain.

### Claim 18 (depends on 16)

The modified cell of claim 16, wherein the cell further comprises a third polynucleotide, wherein the third polynucleotide encodes a chimeric antigen receptor or a recombinant T cell receptor.

### Claim at position 10

-22. (canceled)

### Claim 23 (depends on 16)

The modified cell of claim 16, wherein the cell is a T cell, tumor infiltrating lymphocyte, NK-T cell, or NK cell.

### Claim at position 12

-38. (canceled)

### Claim 39 (depends on 1)

The modified cell of claim 1, wherein the chimeric pro-apoptotic polypeptide comprises a pro-apoptotic polypeptide region, a FKBP12-Rapamycin-Binding (FRB) domain polypeptide, or FRB variant polypeptide region; and the chimeric costimulating polypeptide comprises two FKBP12 variant polypeptide regions and a truncated MyD88 polypeptide region lacking the TIR domain.

### Claim 40 (depends on 39)

The modified cell of claim 39, wherein the chimeric costimulating polypeptide comprises a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain.

### Claim 41 (depends on 39)

The modified cell of claim 39, wherein the FKBP12 variant comprises an amino acid substitution at amino acid residue 36.

### Claim 42 (depends on 41)

The nucleic acid of claim 41, wherein the FKBP12 variant polypeptide region is a FKBP12v36 polypeptide region.

### Claim 43 (depends on 39)

The nucleic acid of claim 39, wherein the FRB variant polypeptide region is selected from the group consisting of KLW (T2098L) (FRBL), KTF (W2101 F), and KLF (T2098L, W2101 F).

### Claim 44 (depends on 39)

The modified cell of claim 39, comprising a polynucleotide that encodes a chimeric antigen receptor or a recombinant TCR.

### Claim 45 (depends on 16)

The modified cell of claim 16, wherein the FKBP12 variant comprises an amino acid substitution at amino acid residue 36.

### Claim 46 (depends on 45)

The modified cell of claim 45, wherein the FKBP12 variant polypeptide region is a FKBP12v36 polypeptide region.

### Claim 47 (depends on 16)

The modified cell of claim 16, wherein the FRB variant polypeptide region is selected from the group consisting of KLW (T2098L) (FRBL), KTF (W2101 F), and KLF (T2098L, W2101 F).

### Claim 48 (depends on 2)

The modified cell of claim 2, wherein the FKBP12 variant polypeptide regions are FKBP12v36 polypeptide regions, and the pro-apoptotic polypeptide region comprises a Caspase-9 polypeptide lacking the CARD domain.

### Claim 49 (depends on 1)

The modified cell of claim 1, wherein in the chimeric pro-apoptotic polypeptide, the FRB polypeptide region or FRB variant polypeptide region, and FKBP12 polypeptide region, are located amino-terminal to the pro-apoptotic polypeptide region; and in the chimeric stimulating polypeptide, the two FKBP12 variant polypeptide regions are located amino-terminal to the costimulatory polypeptide region.

### Claim 50 (depends on 16)

The modified cell of claim 16, wherein in the chimeric pro-apoptotic polypeptide, the FKBP12 variant polypeptide region is located amino-terminal to the pro-apoptotic polypeptide region; and in the chimeric stimulating polypeptide, the FRB polypeptide region or FRB variant polypeptide region, and FKBP12 polypeptide region, are located amino-terminal to the costimulatory polypeptide region.
